β-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis

Insights

Particulate matter (PM) air pollution triggers catecholamine release, activating beta-2 adrenergic receptors (β2AR) on macrophages. This enhances IL-6 release, promoting a prothrombotic state and increasing cardiovascular event risk.

Area of Science:

  • Environmental Health
  • Cardiovascular Research
  • Immunology

Background:

  • Particulate matter (PM) exposure is linked to thrombotic cardiovascular events and mortality.
  • Interleukin-6 (IL-6) release from alveolar macrophages is crucial for PM-induced prothrombotic states.
  • The precise mechanisms connecting PM exposure to cardiovascular dysfunction remain incompletely understood.

Purpose of the Study:

  • To investigate the role of catecholamines and beta-2 adrenergic receptors (β2AR) in mediating PM-induced IL-6 release and prothrombotic effects.
  • To elucidate the signaling pathways involved in β2AR activation in alveolar macrophages following PM exposure.

Main Methods:

  • Murine models and primary human alveolar macrophages were used to assess IL-6 release and prothrombotic status.
  • Experiments involved PM exposure, catecholamine administration, β2AR agonists/antagonists, and genetic manipulation of β2AR.
  • Mitochondrial reactive oxygen species (ROS) generation and adenylyl cyclase activity were measured.

Main Results:

  • PM exposure induced systemic catecholamine release, activating β2AR on murine alveolar macrophages and augmenting IL-6 release.
  • β2AR signaling in mice promoted a prothrombotic state, accelerating arterial thrombosis.
  • In human macrophages, β2AR agonists increased IL-6, while beta-blockers inhibited PM-induced IL-6 release.
  • Genetic or pharmacologic β2AR inhibition attenuated PM-induced IL-6 and prothrombotic responses.
  • β2AR agonists enhanced macrophage responses via mitochondrial ROS and increased adenylyl cyclase activity.

Conclusions:

  • PM exposure activates the sympathetic nervous system through β2AR signaling on alveolar macrophages.
  • This pathway links environmental pollution, inflammation, and metabolic changes to increased susceptibility to thrombotic cardiovascular events.

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K